[Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients].
Hospach
T
T
Olgahospital-Kinderklinik, Stuttgart.
Haas
J P
JP
Huppertz
H I
HI
Keitzer
R
R
Michels
H
H
Trauzeddl
R
R
Föll
D
D
Dannecker
G
G
Horneff
G
G
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D012219:Rheumatology; D012955:Societies, Medical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha